Core Insights - The company reported a significant revenue increase of 63.1% in the first half of 2025, reaching RMB 245.93 million compared to RMB 150.82 million in the same period of 2024 [1] - The continuous glucose monitoring system sales contributed RMB 143.11 million, marking a 91.5% growth from RMB 74.72 million in the previous year [1] - The company's gross profit rose by 57.7% to RMB 127.04 million from RMB 80.56 million year-on-year, driven by increased sales volume and improved operational efficiency [1] Financial Performance - The net loss for the first half of 2025 was reduced to RMB 2.29 million, a 93.9% decrease from a loss of RMB 37.74 million in the same period of 2024 [1] - The improvement in financial performance is attributed to expanded sales scale and enhanced operational management [1] Product and Market Development - As of June 30, 2025, the company holds 21 medical device registrations in China and 60 overseas, with 23 products receiving EU CE marks and 1 product obtaining FDA 510(k) approval [2] - The AiDEX X continuous glucose monitoring system and Equil insulin pump system have seen deepening market penetration, with over 2,500 domestic hospital admissions [2] - International revenue reached RMB 121.29 million, a 218.0% increase from RMB 38.14 million in the previous year, supported by successful market entry in multiple countries [2] Strategic Goals - The company's long-term strategy aims to establish itself as a leading brand in diabetes treatment and monitoring devices in international markets, focusing on Europe and emerging countries [3] - The company plans to leverage its product advantages and market expansion capabilities to benefit from higher healthcare spending and insurance coverage in these regions [3]

Core Viewpoint - 微泰医疗-B (02235) reported significant growth in revenue and gross profit for the first half of 2025, driven by increased sales of glucose monitoring systems both domestically and internationally [1] Financial Performance - Revenue reached approximately 246 million yuan, representing a year-on-year increase of 63.1% [1] - Gross profit was about 127 million yuan, showing a year-on-year growth of 57.7% [1] - The loss attributable to the parent company was approximately 2.29 million yuan, narrowing by 93.9% year-on-year [1] - Earnings per share reflected a loss of 0.005 yuan [1] Operational Efficiency - The reduction in net loss was primarily due to the expansion of the company's sales scale, enhanced budget control, and improved operational efficiency through refined management practices [1]

Core Viewpoint - Microtech Medical-B (02235) reported significant growth in revenue and gross profit for the first half of 2025, driven by increased sales of glucose monitoring systems both domestically and internationally [1] Financial Performance - Revenue reached approximately 246 million yuan, representing a year-on-year increase of 63.1% [1] - Gross profit was about 127 million yuan, showing a year-on-year growth of 57.7% [1] - The loss attributable to the parent company was approximately 2.29 million yuan, narrowing by 93.9% year-on-year [1] - Earnings per share reflected a loss of 0.005 yuan [1] Operational Efficiency - The reduction in net loss was primarily due to the expansion of the company's sales scale, enhanced budget control, and improved operational efficiency through refined management practices [1]

Financial Performance - For the six months ended June 30, 2025, the company reported revenue of RMB 245.93 million, a 63.1% increase from RMB 150.82 million in the same period of 2024[3] - Gross profit for the same period was RMB 127.04 million, up 57.7% from RMB 80.56 million year-on-year[3] - The net loss significantly decreased to RMB 2.29 million, a 93.9% reduction compared to a loss of RMB 37.74 million in the first half of 2024[3] - Operating revenue for the six months ended June 30, 2025, was RMB 245,933,101.49, a 63.1% increase from RMB 150,815,673.60 in the same period of 2024[12] - Operating profit for the same period was a loss of RMB 2,404,719.15, compared to a loss of RMB 37,712,976.97 in 2024, indicating a significant improvement[12] - Net profit for the six months ended June 30, 2025, was a loss of RMB 2,292,687.57, compared to a loss of RMB 37,735,048.47 in 2024, reflecting a substantial reduction in losses[12] - Total revenue for the six months ended June 30, 2025, was RMB 245,933,101.49, a 63.1% increase from RMB 150,815,673.60 in the same period of 2024[21] - Revenue from medical devices and consumables reached RMB 243,617,145.17, up 63.9% from RMB 148,453,653.35 year-over-year[21] Expenses and Cost Management - Sales expenses were RMB 92.81 million, down 7.4% from RMB 100.28 million in the previous year, with the ratio of sales expenses to revenue decreasing from 66.5% to 37.7%[6] - Research and development expenses for the six months ended June 30, 2025, were RMB 32,567,547.27, slightly down from RMB 34,551,341.28 in 2024, indicating a focus on cost management[12] - The company's cost of sales for the same period was RMB 118.89 million, up 69.2% from RMB 70.25 million in 2024, mainly due to increased material costs associated with higher sales volumes[49] - Selling expenses decreased by 7.4% to RMB 92.81 million from RMB 100.28 million in 2024, due to higher market acceptance and efficiency in commercialization of the new AiDEX continuous glucose monitoring system[51] - Management expenses decreased by 7.6% to RMB 18.20 million from RMB 19.70 million in 2024, resulting from enhanced operational efficiency through comprehensive budget control[52] - Research and development expenses decreased by 5.7% to RMB 32.57 million from RMB 34.55 million in 2024, mainly due to reduced phase-specific investments in R&D materials[53] Assets and Liabilities - Total assets as of June 30, 2025, amounted to RMB 2,207,723,239.12, an increase from RMB 2,146,352,845.61 at the end of 2024[14] - Current assets totaled RMB 1,953,639,250.29 as of June 30, 2025, compared to RMB 1,904,814,042.37 at the end of 2024, showing a growth in liquidity[14] - Total liabilities increased to RMB 238,366,025.44 as of June 30, 2025, from RMB 171,722,463.18 at the end of 2024, indicating a rise in financial obligations[15] - As of June 30, 2025, accounts payable totaled approximately $101.02 million, up from $77.05 million as of December 31, 2024, representing a 31.1% increase[28] Product Development and Innovation - The company is advancing its research and development pipeline, with significant clinical progress in the AiDEX X continuous glucose monitoring system and the Equil insulin pump system[7] - The company has developed a comprehensive product portfolio in diabetes management, including 21 registered medical devices in China and 60 overseas, with 23 products receiving EU CE marking and 1 product approved by the US FDA[30] - The core product, the Equil insulin pump system, has a longer reusable lifespan and unique vibration alarm design, with registration applications submitted for pediatric use and a second-generation system[32] - The AiDEX continuous glucose monitoring system is the second commercialized system globally that offers real-time, calibration-free monitoring, with expanded indications for children and adolescents approved in 2024[33] - The PanCares closed-loop artificial pancreas system integrates monitoring and treatment functions, utilizing adaptive model predictive control algorithms for dynamic blood glucose management, with registration submitted to the regulatory authority[35] - The company has commercialized 15 types of blood glucose meters and 7 types of test strips in China, with additional products developed for overseas markets, enhancing access to a broader diabetes patient population[36] - The Exactive Pro system, developed by the company, received EU CE certification in 2022 and national drug administration approval in 2023, making it the first integrated product in China to monitor blood glucose, ketones, and uric acid simultaneously[37] - The company's "全院血糖管理系統" has been approved by the Zhejiang Drug Administration, enabling real-time monitoring and remote data sharing for diabetes management[39] Market Expansion and Strategy - The company achieved international revenue of RMB 121.29 million, a remarkable 218.0% increase from RMB 38.14 million in the first half of 2024[10] - The company expanded its product reach to over 2,500 hospitals domestically and sold products to 118 countries globally[8] - The company is actively participating in international exhibitions and has made significant inroads into emerging markets in the Middle East, Asia-Pacific, and South America[46] - The company has established a comprehensive e-commerce strategy, enhancing user engagement and brand conversion efficiency[9] - The company has diversified its e-commerce strategy, achieving significant sales growth compared to the first half of 2024[45] - The company is focused on increasing market share and brand reputation for its insulin pump and continuous glucose monitoring systems, with expected rapid sales growth driven by improved patient awareness and clinical effectiveness[66] Corporate Recognition and Governance - The company was recognized as a "National-level Specialized and Innovative Small Giant Enterprise" by the National Sports Administration, reflecting its commitment to social responsibility and innovation[11] - The company has been recognized as a national-level "little giant" enterprise, indicating its strong innovation capabilities in the diabetes treatment device sector[42] - The audit committee reviewed the unaudited interim consolidated financial results for the six months ending June 30, 2025, confirming compliance with accounting standards and regulations[80] - The board of directors did not recommend the distribution of an interim dividend for the six months ending June 30, 2025, consistent with the previous period[79] Customer Engagement and Support - A 24/7 customer service team has been established to provide consultation and support for end-users, enhancing customer satisfaction through data-driven service optimization[67]

Group 1 - The company, MicroTech Medical-B (02235.HK), announced that it will hold a board meeting on August 29, 2025, to review and approve the unaudited interim results for the six months ending June 30, 2025 [1] - The board meeting will also consider the proposal for an interim dividend distribution, if applicable [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部份內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 微 泰 醫 療 器 械（ 杭 州 ）股 份 有 限 公 司 （ 於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司 ） （股份代號： 2235） 承董事會命 微泰醫療器械（杭州）股份有限公司 MicroTech Medical (Hangzhou) Co., Ltd. 董事長 董事會會議召開日期 微泰醫療器械（杭州）股份有限公司（「本公司」）董事會（「董事會」）謹此宣佈， 本公司將於2025年8月29日（星期五）舉行董事會會議，其中包括審議及批准本 公司及其附屬公司截至2025年6月30日止六個月之未經審計的中期業績及其發 佈，並考慮建議派發中期股息（如有）。 鄭攀 中國，杭州，2025年8月18日 於本公告日期，本公司執行董事為鄭攀博士、于非博士、施永輝博士及劉秀女士；本公司非 執行董事為毛碩先生及高韻女士；及本公司獨立非執行董事為厲力華博士、王春鳳女士、何 建昌先生及程華博士 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 微泰醫療器械（杭州）股份有限公司 (於中華人民共和國注冊成立) 呈交日期: 2025年8月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02235 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 169,235,842 | RMB | | 1 RMB | | 169,235,842 | | 增加 / 減少 (-) | | | | | | RMB | | | | 本月底結存 | | | 169,235,842 | RMB | | 1 RMB | | 169,235,842 | | 2. 股份分類 | 普通股 | ...

Core Points - The company, Weitai Medical Devices (Hangzhou) Co., Ltd., has initiated a voluntary recall of its subcutaneous infusion sets for insulin pumps due to potential non-compliance with product technical requirements [1] - The recall is classified as a Class III recall, which indicates that the products involved do not pose a significant risk of injury or illness [1] - A total of 25,660 sets of the affected product, registered under the certificate number National Medical Device Approval 20173143333, were sold in China [1] Summary by Category - **Product Recall** - The company has proactively recalled the insulin pump subcutaneous infusion sets due to UV absorbance results that may not meet technical standards [1] - The recall is classified as Class III, indicating a lower risk level [1] - **Sales Impact** - The recall affects 25,660 units sold in the Chinese market [1] - Detailed information regarding the models, specifications, and batches of the recalled products is available in the Medical Device Recall Event Report [1]

Financial Performance - In the fiscal year 2024, the company reported total revenue of 346 million yuan, representing a year-on-year growth of 36.48% [2] - The net profit attributable to shareholders was a loss of 63.12 million yuan, an improvement from a loss of 125 million yuan in the same period last year [2] - The net cash flow from operating activities was -121 million yuan, an improvement from -153 million yuan in the previous year [2] - The basic earnings per share were -0.15 yuan, with a weighted average return on equity of -3.09% [2][18] Valuation Metrics - As of April 30, 2024, the company's price-to-book ratio (TTM) was approximately 1.22 times, and the price-to-sales ratio (TTM) was about 6.99 times [2] Revenue Composition - The revenue composition for 2024 included 340.7 million yuan from the sale of medical devices and consumables, with minimal contributions from other services and rental payments [12] Cash Flow Analysis - The net cash flow from financing activities was -33.15 million yuan, a decrease of 9.69 million yuan compared to the previous year [22] - The net cash flow from investment activities was 121 million yuan, compared to -541 million yuan in the previous year [22] Asset and Liability Changes - As of the end of 2024, cash and cash equivalents decreased by 10%, while accounts receivable increased by 58.54% [30] - The company saw a significant increase in contract liabilities by 241.53% and accounts payable by 112.32% [33] Financial Ratios - The current ratio was reported at 11.41, and the quick ratio was 11.11, indicating a strong liquidity position [36]

Financial Performance - Revenue for 2024 reached RMB 345.615 million, a 36.4% increase from RMB 253.228 million in 2023[12] - Gross profit for 2024 was RMB 182.849 million, up 51.5% from RMB 120.665 million in 2023[12] - The net loss for 2024 decreased to RMB 63.118 million from RMB 125.016 million in 2023, indicating improved profitability[12] - The company's operating revenue for the year ending December 31, 2024, was RMB 345.62 million, a 36.5% increase from RMB 253.23 million for the year ending December 31, 2023, primarily driven by the launch and commercialization of the new generation continuous glucose monitoring system AiDEX X[43] - The continuous glucose monitoring system generated RMB 180.43 million in revenue, accounting for 52% of total revenue, compared to RMB 75.71 million and 30% in the previous year[44] - The gross profit for the year ending December 31, 2024, was RMB 182.85 million, a 51.5% increase from RMB 120.67 million in the previous year, with the gross margin improving from 47.7% to 52.9%[46] - The company's operating costs increased by 22.8% to RMB 162.77 million, up from RMB 132.56 million, mainly due to increased labor and material costs driven by higher sales volumes[45] - Research and development expenses rose by 9.2% to RMB 76.56 million, up from RMB 70.10 million, reflecting ongoing product development and clinical trials[48] Market Expansion and Product Development - Cumulative users of the continuous glucose monitoring system exceeded 600,000, driving a 138% year-on-year increase in sales revenue[8] - The company has expanded its product coverage to 108 countries and regions, enhancing its international market presence[8] - The number of hospitals cooperating with the diabetes digital management platform surpassed 2,200, increasing the scale of healthcare personnel served from over 7,000 to over 10,000[8] - The company plans to accelerate the development and clinical registration of new products, including the CGM and PanCares artificial pancreas system, in 2025[9] - The company aims to expand its market share and brand reputation for core products, with a projected annual growth rate of over 20% for continuous glucose monitoring systems in China[64] - The company has successfully entered markets in 108 countries, including Europe, the Middle East, Africa, Asia, and Latin America, with positive feedback on its Equil brand products from local doctors and patients[66] - The company plans to enhance its product portfolio by advancing the development and clinical registration of new products, including the second-generation patch insulin pump system and the new AiDEX X continuous glucose monitoring system[68] - The company is focused on upgrading diabetes management through an innovative model combining devices, algorithms, and cloud platforms, aiming to improve monitoring and management efficiency[69] Research and Development - R&D investment for the reporting period was RMB 76.56 million, an increase from RMB 70.10 million in 2023, primarily for personnel expenses and ongoing product development[34] - The company aims to integrate advanced analytics and AI algorithms into its cloud-based artificial pancreas solution for personalized glucose management[22] - The company’s product pipeline includes five major categories, focusing on diabetes monitoring, treatment, and management technologies[16] - The new generation AiDEX X continuous glucose monitoring system has entered rapid commercialization after receiving approvals from national and EU authorities[32] Corporate Governance and Management - The company has a strong focus on strategic planning, international business development, and capital market activities led by Dr. Shi Yonghui, the Chief Strategic Development Officer[78] - The financial management is overseen by Ms. Liu Xiu, who has over 18 years of experience in finance and investment[80] - The leadership team includes experienced professionals with backgrounds in biomedical engineering and strategic consulting, contributing to the company's growth strategy[85] - The company is committed to maintaining high standards of corporate governance and transparency in its operations[85] - The board of directors includes independent members who provide oversight and strategic guidance on corporate governance and audit matters[85] - The company has established specific terms of reference for its four board committees, ensuring clear definitions of their powers and responsibilities[124] - The board has maintained a balanced diversity among its members, considering various factors such as skills, experience, and gender[135] Risk Management and Compliance - The board acknowledges its responsibility for risk management and internal control systems, which aim to manage significant risks rather than eliminate them[147] - The company has adopted a series of risk management policies to continuously identify, assess, and monitor key risks related to its strategic objectives[150] - The company has established a risk management and internal control system, which is reviewed annually, and is deemed effective and sufficient for the year ending December 31, 2024[154] - The company has implemented various internal control measures across its business operations, including employee training on compliance with policies related to intellectual property protection and environmental safety[152] - The company has a strict anti-corruption policy for sales and marketing activities, requiring distributors to provide written commitments to adhere to the company's standards[152] Sustainability and Social Responsibility - The company is committed to sustainability, with plans to reduce operational carbon emissions by 25% over the next three years[104] - The company is committed to integrating social responsibility into its business development strategies and human resource management[183] - The company has established an ESG supervisory committee to oversee and implement ESG strategies, consisting of the CFO, securities officer, legal officer, and administrative executive[185] - The company identified 23 material issues based on industry trends, national regulations, and international standards to enhance sustainable development performance[189] - The company engages with stakeholders to understand their concerns and expectations, ensuring transparency and accountability in operations[186][188] Shareholder Engagement - The company communicates with shareholders through various channels, ensuring their rights are protected during significant matters presented at the annual general meeting[162] - The company has established a website for public access to the latest information regarding its operations and financial data[171] - The company emphasizes the importance of effective communication with shareholders to enhance understanding of its business performance and strategies[171] - The company has a policy for shareholders to propose extraordinary general meetings if the board does not respond within a specified timeframe[166]